A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
Journal Article
·
· Science Translational Medicine
- Icahn School of Medicine at Mount Sinai, New York, NY (United States)
- Univ. of North Carolina, Chapel Hill, NC (United States)
Interactions between WD40 repeat domain protein 5 (WDR5) and its various partners such as mixed lineage leukemia (MLL) and c-MYC are essential for sustaining oncogenesis in human cancers. However, inhibitors that block protein-protein interactions (PPIs) between WDR5 and its binding partners exhibit modest cancer cell killing effects and lack in vivo efficacy. Here, we present pharmacological degradation of WDR5 as a promising therapeutic strategy for treating WDR5-dependent tumors and report two high-resolution crystal structures of WDR5-degrader-E3 ligase ternary complexes. We identified an effective WDR5 degrader via structure-based design and demonstrated its in vitro and in vivo antitumor activities. On the basis of the crystal structure of an initial WDR5 degrader in complex with WDR5 and the E3 ligase von Hippel–Lindau (VHL), we designed a WDR5 degrader, MS67, and demonstrated the high cooperativity of MS67 binding to WDR5 and VHL by another ternary complex structure and biophysical characterization. MS67 potently and selectively depleted WDR5 and was more effective than WDR5 PPI inhibitors in suppressing transcription of WDR5-regulated genes, decreasing the chromatin-bound fraction of MLL complex components and c-MYC, and inhibiting the proliferation of cancer cells. In addition, MS67 suppressed malignant growth of MLL-rearranged acute myeloid leukemia patient cells in vitro and in vivo and was well tolerated in vivo. Collectively, our results demonstrate that structure-based design can be an effective strategy to identify highly active degraders and suggest that pharmacological degradation of WDR5 might be a promising treatment for WDR5-dependent cancers.
- Research Organization:
- Brookhaven National Laboratory (BNL), Upton, NY (United States)
- Sponsoring Organization:
- USDOE Office of Science (SC), Basic Energy Sciences (BES). Scientific User Facilities Division
- Grant/Contract Number:
- SC0012704
- OSTI ID:
- 1837161
- Report Number(s):
- BNL-222545-2021-JACI
- Journal Information:
- Science Translational Medicine, Journal Name: Science Translational Medicine Journal Issue: 613 Vol. 13; ISSN 1946-6234
- Publisher:
- AAASCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models
Journal Article
·
Thu Dec 19 19:00:00 EST 2019
· Journal of Medicinal Chemistry
·
OSTI ID:1598029
Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Journal Article
·
Mon Oct 15 00:00:00 EDT 2018
· Biochemical and Biophysical Research Communications
·
OSTI ID:23107799
Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models
Journal Article
·
Mon Dec 26 19:00:00 EST 2022
· Proceedings of the National Academy of Sciences of the United States of America
·
OSTI ID:2470237